Effective treatment of Kaposi's sarcoma with 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388).
D000328:Adult; D000577:Amides / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001772:Blood Cell Count; D003609:Dactinomycin / Q000627:therapeutic use; D004351:Drug Resistance; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012075:Remission, Spontaneous; D012514:Sarcoma, Kaposi / Q000188:drug therapy*; D012878:Skin Neoplasms / Q000188:drug therapy; D014226:Triazenes / Q000009:adverse effects / Q000627:therapeutic use*
D000577:Amides; D000970:Antineoplastic Agents; D007093:Imidazoles; D014226:Triazenes; D003609:Dactinomycin